360 related articles for article (PubMed ID: 33579912)
1. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
[TBL] [Abstract][Full Text] [Related]
2. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
3. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
4. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Banasavadi-Siddegowda YK; Russell L; Frair E; Karkhanis VA; Relation T; Yoo JY; Zhang J; Sif S; Imitola J; Baiocchi R; Kaur B
Oncogene; 2017 Jan; 36(2):263-274. PubMed ID: 27292259
[TBL] [Abstract][Full Text] [Related]
5. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
6. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
8. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Braun CJ; Stanciu M; Boutz PL; Patterson JC; Calligaris D; Higuchi F; Neupane R; Fenoglio S; Cahill DP; Wakimoto H; Agar NYR; Yaffe MB; Sharp PA; Hemann MT; Lees JA
Cancer Cell; 2017 Oct; 32(4):411-426.e11. PubMed ID: 28966034
[TBL] [Abstract][Full Text] [Related]
9. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
12. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
14. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
16. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
17. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
18. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
19. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
20. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
